Opaleye Management’s Immunovant IMVT Stock Holding History

Opaleye Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-467,000	Closed	-$7.49M	–	55
2021 Q1	$7.49M	Buy	+467,000	New	+$12.3M	1.1%	29

Other funds holding IMVT

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Opaleye Management's IMVT Position: Q2 2021 in Review

Opaleye Management sold out of Immunovant (IMVT) in Q2 2021, closing a stake of 467,000 shares — an estimated $7.49M sold.

Opaleye Management first reported a position in IMVT in Q1 2021 and held it in 1 quarter. The position peaked at $7.49M in Q1 2021. 110 funds tracked by Wall St. Rank hold IMVT as of Q2 2021.

Opaleye Management reported no remaining Immunovant position as of Q2 2021 after selling out during the quarter.
Opaleye Management sold 467,000 Immunovant shares in Q2 2021, an estimated $7.49M.
Opaleye Management first reported a position in Immunovant in Q1 2021 and held it in 1 quarter.
Opaleye Management's Immunovant position peaked at $7.49M in Q1 2021.
110 funds tracked by Wall St. Rank held Immunovant as of Q2 2021.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.